Adlai Nortye (NASDAQ:ANL) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Adlai Nortye (NASDAQ:ANL) in a report released on Friday, Marketbeat reports. The firm currently has a $9.00 price objective on the stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a research report on Thursday, June 20th.

Adlai Nortye Stock Performance

Shares of Adlai Nortye stock opened at $1.95 on Friday. The business has a 50-day moving average price of $2.39 and a two-hundred day moving average price of $5.71. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.